DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cellcept (Mycophenolate Mofetil Hydrochloride) - Summary

 

-- advertisement --

WARNING

Immunosuppression may lead to increased susceptibility to infection and possible development of lymphoma. Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should use CellCept. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.

Female users of childbearing potential must use contraception. Use of CellCept during pregnancy is associated with increased risk of pregnancy loss and congenital malformations.

 

CELLCEPT SUMMARY

CellCept (mycophenolate mofetil) is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent; inosine monophosphate dehydrogenase (IMPDH) inhibitor.

Renal, Cardiac, and Hepatic Transplant:    CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.

CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication.

CELLCEPT NEWS HIGHLIGHTS

Media Articles Related to Cellcept (Mycophenolate Mofetil)

mycophenolate mofetil-oral, Cellcept
Source: MedicineNet Bullous Pemphigoid Specialty [2005.03.02]

Ovarian Function Preserved In Women With Severe Systemic Lupus Erythematosus When Treated With Cyclophosphamide And Mycophenolate Mofetil
Source: Lupus News From Medical News Today [2008.06.13]

EHealth Global Shows Dramatic Growth Of EHealthConnect™ Services For Solid Organ Transplant Departments
Source: Transplants / Organ Donations News From Medical News Today [2008.10.01]

CMV Disease In Solid Organ Transplant Recipients: A Proactive Approach To Prevention
Source: Transplants / Organ Donations News From Medical News Today [2008.09.24]

Researchers Find Link Between Organ Transplants, Cancer
Source: MedicineNet Kidney Cancer Specialty [2008.07.17]

more>>

Published Studies Related to Cellcept (Mycophenolate Mofetil)

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. [2008.08.05]

Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome. [2008.07.12]

Mycophenolate Mofetil Monotherapy in Membranous Nephropathy: A 1-Year Randomized Controlled Trial. [2008.06.26]

CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A. [2008.06]

Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. [2008.06]

more>>

Clinical Trials Related to Cellcept (Mycophenolate Mofetil)

A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . . [Terminated]

A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS. [Terminated]

Myfortic vs. Cellcept in Kidney Transplant Recipients [Completed]

Study of Therapeutic Monitoring of CellCept (Mycophenolate Mofetil) After Kidney Transplantation [Completed]

A Study of CellCept (Mycophenolate Mofetil) in Management of Patients With Lupus Nephritis. [Active, not recruiting]

more>>

Page last updated: 2008-10-01

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008